

HARRY C. BOGHIGIAN

7 Tudor Place
Randolph, NJ 07869-2020
Cell: 973-476-6591
E-Mail: Hcbog@pharmaconsultantsllc.com, PHRMCNSLTNT@aol.co

23850 Via Italia Circle Suite 406
Bonita Springs, Florida 34134
Office: 239 676-7284
E-Mail: Hcbog@aol.com

Policy level Senior Executive and Chief Operating Officer with extensive experience in general management, sales, marketing, direct to consumer advertising, strategic planning and business execution. Demonstrated record of accomplishment in exceeding business targets and producing impressive business results. A driving passion for delivering incremental value. Strong analytical skills with broad experience in developing and leading high performance teams. A creative, high energy, versatile and action oriented business leader providing broad perspective, change leadership and desired outcomes.

EXPERIENCE

PBN PHARMA LLC, Chicago, IL President	2003-
PHARMA CONSULTANTS LLC, Randolph, NJ President	2001-
ROCHE PHARMA, INC., Nutley, NJ Vice President, Business Operations Vice President, Marketing Vice President, Southern Business Operations	1995-2001
HOFFMANN-LA ROCHE, Toronto, Canada Sr. Vice President & General Manager, Roche Pharmaceuticals, Canada	1991-1994
HOFFMANN-LA ROCHE, Basel, Switzerland Group Director & Global Business Representative	1989-1991
ROCHE LABS, Nutley, NJ Product Director Regional Sales Director Manager, Market Research	1984-1989
HOFFMANN-LA ROCHE, Nutley, NJ Division Sales Manager, FL Sales Representative, MA, NH, ME	1971-1984

ACCOMPLISHMENTS

- Significant general management and operations experience.
- Recognized Industry leader in field sales and marketing.
- Proven track-record of leadership inspiring people to over-achieve.
- Created and built high performance teams and enhanced organizational structure.
- Consistently identified and developed hidden revenue opportunities into development and commercialized prescription products.
- Revitalized the most successful co-promotion arrangement in history of the pharmaceutical industry.
- Consistently applauded for achieving revenue and profit targets.
- Successfully managed small and large pharmaceutical organizations.
- Significant experience in integration of corporate acquisitions.

HARRY C. BOGHIGIAN

Page Two

PBN PHARMA LLC, Chicago, IL

President

Research & Development Company focused on the marketing, licensing and divestiture of patented prescription and over-the-counter healthcare products covering a wide range of therapeutic areas PBN has a number of patented and patent pending products in various stages of development. Therapeutic areas include skin care, pain management and drug delivery systems. PBN introduced its first product in 2011 and a second in 2013.

PHARMA CONSULTANTS LLC, Randolph, NJ

President

Specializing in developing and consulting on strategies and tactics for prescription, OTC, and healthcare related products. Custom work servicing advertising agencies, biotech, pharmaceutical and health related companies and expert reports for international law firms on behalf of their clients.

ROCHE PHARMA, INC., Nutley, NJ

Vice President Business Operations

Profit and Loss responsibility for Business Operations representing Eastern half of United States with revenues in excess of \$1 billion and 55% of corporate revenues. Managed a \$130 million operating budget and refined execution of product strategies and tactics. Established expectations for hiring, managing, training and personal development of a 900 member field sales organization located within 10 regional business unit offices. Served as a member of the Business Operating Group, Business Strategic Forum, Strategic Alignment Steering Committee, Business Planning Process Committee and SB / Roche Steering Committee, Transformation 2000 Task Force.

- Driving force in Sales Force Transformation 2000 Project resulting in record productivity for managers and representatives.
- Recognized outpatient opportunities for prescribing of Rocephin IV and IM in Michigan, New York and Ohio resulting in three million dollars in incremental revenue and basis for national strategy to be implemented fourth quarter 2001.
- Achieved record levels in new prescription growth with Xenical (42.5%) and Tamiflu (74.6%) by implementing strategy of high frequency call activity and diverse programs on a limited target audience.
- Created Business Development Specialist to focus on non-traditional business customers capitalizing on untapped markets.
- Established enhanced focus on customer service with representative and account managers, resulting in several million dollars in incremental revenue.
- Developed and promoted three Business Unit Directors to Vice President.

Vice President U.S. Marketing

Corporate officer with total responsibility for re-building and reenergizing the marketing department, development of market strategies, 5 year revenue plans, and consulting with President and CEO on status of pharmaceutical business. Responsible for \$2.3 billion portfolio of products. Sales increased 20% annually.

- Reorganized and staffed Marketing Intelligence, Career Training and Development, Sales Administration, Marketing, Promotion and Communications Department.
- Created and staffed first New Product Development & Planning, Consumer Marketing Leadership Center, Strategic Product Life Extension Group and Promotional Budget Management Departments.
- Directed hiring 60 high-grade individuals within 18-month period resulting in a First Class fully resourced Marketing Department totaling 270 full time and 45 full time contract employees in print department.
- Developed and implemented innovative strategies which delayed generic competition of Ticlid for 18 months representing an incremental \$175 million in revenues.
- Created Marketing Operating Committee that successfully oversaw day-to-day operations of product marketing teams and service departments resulting in greater efficiencies and program synergies.
- Created and implemented extensive communication program and vision of "Becoming the Most Formidable Marketing Department in the Industry."

HARRY C. BOGHIGIAN

Page Three

- Supervised the development of standards for numerous job functions related to budget and brand-lifecycle management.
- Developed comprehensive five-year revenue plans and strategies for major brands and presented them to Chairman and CEO.
- Successfully launched Posicor, Tasmar, Versed Syrup, Rocephin AOM, and Xenical (then the third most successful launch in pharmaceutical history). Oversaw Tamiflu launch plans.
- Supervised operating budget in excess of \$50 million and promotional budgets of over \$343 million resulting in a \$12 million savings the first year and a \$22 million savings in second year.
- Primary Care revenues grew 20% annually in '97 and '98 closing revenue gap of \$250 million due to Posicor withdrawal from market and delay in Xenical introduction.
- Developed strategies and tactics, which slowed generic erosion of products off patent and provided \$10.5+ million in incremental revenues.
- Directed development of Klonopin to Zydis Drug Delivery System - launching 4Q 2001. Estimate first twelve months revenue at \$55 million.

Vice President – Southern Business Operations

One of four senior executives that created and executed a new pharmaceutical business model for U.S. pharmaceutical business. Successful achievement of aggressive revenue and profit targets.

- Successfully launched five new products in 12 months and achieved revenue targets of \$1.3 billion, a 16% increase.
- Installed and staffed twenty business unit offices across U.S.
- Created and implemented job descriptions, performance expectations and standards for entire pharmaceutical business operations group.
- Convinced senior management to add 56 incremental representatives in seven southern states with net return of \$3 to 1. Became model for national expansion.

HOFFMANN-LA ROCHE, Toronto, Canada

Sr. Vice President and General Manager Roche Pharmaceuticals Canada

General manager of pharmaceutical business responsible for sales, marketing, regulatory affairs, new business development, medical, professional services, federal and provincial government affairs, pricing, health economics, contracting, revenue growth, business expenses and profit and loss. Sales increased 82%.

- Hired new head of marketing and sales and reorganized management team.
- Created and chaired Marketing Board, a body of five department heads responsible for success of pharmaceutical business.
- Oversaw development of strategies and tactics resulting in successful launch of Mobiflex, Inhibace and Mannerix.
- Increased Rocephin sales 25% by hiring health economist and instituting a contracting program for hospitals.
- Successfully increased overall sales 82%.
- Integrated Syntex Pharmaceutical into Roche Organization resulting in a new company budget of \$225 million and reorganized sales force.

HOFFMANN-LA ROCHE, Basel, Switzerland

Group Director & Global Business Representative

Responsible for revenue forecasts strategies and tactic of marketed and developmental compounds in cardiovascular, metabolic, gastrointestinal, central nervous system and oral anti-infectives.

- Responsibility for development worldwide Xenical lifecycle forecast and US market development plans.
- Convinced global R&D to spend additional \$9.5 million in two additional arms of the phase three studies of Xenical resulting in an incremental \$50 million.

HARRY C. BOGHIGIAN

Page Four

- Revitalized the Roche/Glaxo co-promotion arrangement for Zantac and Ceftin. The most successful co – promotion arrangement in pharmaceutical history.

ROCHE LABS, Nutley, NJ

Product Director

Developed strategic plans for marketed products and new brands in gastroenterology, cardiology, infectious disease, and CNS.

- Coordinated clinical development for Roche/Glaxo co-promotion of Zantac and Ceftin.
- Spearheaded successful physician and pharmacy educational symposia that ran across the country for three years.
- Responsible for long-term revenue projections and evaluating licensing and acquisition candidates.

Regional Sales Director

- Directed 120 sales representatives with responsibility for 11 products and \$215 million annual sales.
- Controlled an operating budget of \$8 million.

Manager, Market Research

- Directed a team of analysts to uncover opportunities, strategies and messages for existing and new prescription brands.

HOFFMANN-LA ROCHE, Nutley, NJ

Division Sales Manager, West Coast Florida

- Managed twelve sales representative covering gulf coast of Florida.
- Launched Rocephin (the #1 injectable antibiotic).

Sales Representative, MA, NH & ME

- A consistent record of exceeding sales quotas. Received President's Achievement Award four times. Highest company sales award.
- Responsible for selling pharmaceuticals, educational training materials (ROCOM) and clinical laboratory services. (RCL)
- Sold clinical laboratory services to physicians and hospitals. Established first clinical laboratory drawing station in New England.

EDUCATION

Bachelor of Science, Whittemore School of Business, University of New Hampshire

Post Graduate Courses

Executive Business Program

Insead, European Institute of Business Administration, Fontainebleau Cedex, France

Rising To Leadership Challenge

London Business School, London England

Type II Diabetes in the 90's

Harvard Medical School, Cambridge, Massachusetts

Executive Leadership Program

IMD, Lausanne, Switzerland

HARRY C. BOGHIGIAN

Page Five

Leading Organizational Change & Renewal
Harvard Business School, Cambridge, Massachusetts

Pharmacology and Pharmacodynamics of CNS Acting Drugs
University of Rochester Medical School, Rochester, New York

Infections and Treatments of the Nineties
Baylor College of Medicine, Houston, Texas

Pharmaceutical Marketing
Dartmouth College, Tuck School of Business, Hanover, New Hampshire

PROFESSIONAL ASSOCIATIONS

Healthcare Marketing Council, International Executive Guild
UNH Whittemore School of Business & Economics Judge for Paul J. Holloway Business Plan Competition
Chemist Club

ADVISORY BOARDS

University New Hampshire Alumni

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.